About Zenas Biopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://zenasbio.com/
Frequently Asked Questions
What is the 52-week range for ZBIO?
The 52-week high is $44.6 and the 52-week low is $13.5.
What is the P/E ratio for ZBIO?
The P/E ratio data is currently unavailable.
What is the dividend yield for ZBIO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -189.68%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -11145.60%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 8.05.
Analyst Recommendation Trends
Wall Street analyst consensus for ZBIO over the last few months:
Latest ZBIO News
Citigroup Maintains Buy on Zenas BioPharma, Raises Price Target to $48
Citigroup analyst Yigal Nochomovitz maintains Zenas BioPharma (NASDAQ:ZBIO) with a Buy and raises the price target from $41 to $48.
Wedbush Reiterates Outperform on Zenas BioPharma, Maintains $45 Price Target
Wedbush analyst Martin Fan reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Outperform and maintains $45 price target.
HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease September 29, 2026 8:00 AM...
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
When biotechnology innovators approach the commercialization cliff, market participants must weigh the clinical promise of a lead asset against the stark realities of surging operating expenses and capital dilution. Zenas BioPharma (NASDAQ:ZBIO) finds itself at this critical juncture, balancing robust Phase 3 trial data and expanding international licensing partnerships against widening net losses and complex […]
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?
Zenas BioPharma (NasdaqGS:ZBIO) filed shelf registrations totaling more than US$240 million, according to recent regulatory disclosures. The filings include a broad shelf registration for potential future securities offerings across multiple instruments. A separate portion of the shelf is earmarked for an employee stock ownership plan related offering. The new shelf registrations and ESOP related shelf tell only part of the Zenas BioPharma story for investors to weigh. Our analysis turns up...
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – – Additional analyses will assess glucocorticoid-associated toxicity and vaccine responses – WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmune and inflammatory diseases, today announc
Zenas BioPharma To Present New Data From Phase 3 INDIGO Trial Evaluating Obexelimab In IgG4-RD At 6th International Symposium On IgG4-Related Disease, And ACR Convergence 2026
– New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –– Additional analyses will assess glucocorticoid-associated toxicity and
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that on September 15, 2026 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase
Zenas BioPharma, Inc. (ZBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zenas BioPharma, Inc. (ZBIO) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 4:05 PM EDTCompany ParticipantsLeon Moulder -...
Zenas BioPharma Registers Resale Of Up To 7M Shares By Selling Stocholder
ZENAS BIOPHARMA, INC.Up to 7,000,000 Shares of Common StockThis prospectus relates to the resale or other disposition from time to time of up to 7,000,000 shares (the "Shares") of our common stock, par value
Zenas BioPharma, Inc. (ZBIO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Zenas BioPharma, Inc. (ZBIO) Citigroup's Biopharma Back to School Summit 2026 September 9, 2026 4:20 PM EDTCompany ParticipantsLeon Moulder - Founder, CEO...
Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced that it will host an Obexelimab IgG4-RD Investor Event virtually on Tuesday, September 29, 2026, from 8:00 – 9:30 a.m. ET. Zenas’ management team will be join
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for patients living with autoimmune and inflammatory diseases, today announced management’s presentations at the following investor conferences: Citi Biopharma Back to School Conference on Wednesday, September 9, 2026, at 4:20 p.m. ETMor
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-01 | Oliger Christy J. | +37,000 | - | - |
| 2026-06-15 | ORLOFF JOHN J | +18,500 | - | - |
| 2026-06-15 | Nunn Jason Raleigh | +18,500 | - | - |
| 2026-06-15 | Allen Patricia L | +18,500 | - | - |
| 2026-06-15 | Farmer Joseph L | +175,000 | - | - |
| 2026-06-15 | ENRIGHT PATRICK G | +18,500 | - | - |
| 2026-06-15 | MOULDER LEON O JR | +500,000 | - | - |
| 2026-05-18 | MOULDER LEON O JR | +60,000 | $16.88 | $1,012,800 |
| 2026-04-29 | MOULDER LEON O JR | +35,000 | $17.62 | $616,700 |
| 2026-04-28 | MOULDER LEON O JR | +25,000 | $18.02 | $450,500 |
| 2026-03-31 | Lu Hongbo | +3,768 | $18.63 | $70,198 |
| 2026-03-31 | Harwin Peter Evan | +150,000 | $20 | $3,000,000 |
| 2026-03-31 | Lu Hongbo | +75,000 | $20 | $1,500,000 |
| 2026-03-31 | MOULDER LEON O JR | +34,000 | $19.31 | $656,540 |
| 2026-03-30 | MOULDER LEON O JR | +20,000 | $18.23 | $364,600 |
| 2026-02-13 | Allen Patricia L | +4,160 | $26.36 | $109,658 |
| 2026-02-12 | Allen Patricia L | +5,000 | $26.5 | $132,500 |
| 2026-02-12 | Allen Patricia L | +5,700 | $24.34 | $138,738 |
| 2026-02-12 | Allen Patricia L | +5,000 | $23.77 | $118,850 |
| 2026-02-11 | Lu Hongbo | +25,985 | $22.5 | $584,663 |
| 2026-02-05 | Farmer Joseph L | +974 | $13.35 | $13,003 |
| 2026-02-02 | MOULDER LEON O JR | +57,000 | $17.96 | $1,023,720 |
| 2026-01-09 | MOULDER LEON O JR | +20,000 | $16.55 | $331,000 |
| 2026-01-08 | MOULDER LEON O JR | +30,000 | $16.3 | $489,000 |
| 2026-01-07 | MOULDER LEON O JR | +50,000 | $16.38 | $819,000 |
| 2025-10-09 | George Simeon | +63,157 | $19 | $1,199,983 |
| 2025-10-09 | George Simeon | +63,158 | $19 | $1,200,002 |
| 2025-10-09 | Nunn Jason Raleigh | +63,158 | $19 | $1,200,002 |
| 2025-10-09 | ENRIGHT PATRICK G | +11,990 | $20.85 | $249,992 |
| 2025-10-09 | ENRIGHT PATRICK G | +105,265 | $19 | $2,000,035 |
| 2025-10-07 | Lu Hongbo | +263,160 | $19 | $5,000,040 |
| 2025-10-07 | Harwin Peter Evan | +316,219 | $19 | $6,008,161 |
| 2025-10-07 | MOULDER LEON O JR | +36,928 | $20.85 | $769,949 |